These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 30220235)

  • 1. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
    Kolb M; Raghu G; Wells AU; Behr J; Richeldi L; Schinzel B; Quaresma M; Stowasser S; Martinez FJ;
    N Engl J Med; 2018 Nov; 379(18):1722-1731. PubMed ID: 30220235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
    Behr J; Kolb M; Song JW; Luppi F; Schinzel B; Stowasser S; Quaresma M; Martinez FJ
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1505-1512. PubMed ID: 31365829
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
    Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
    N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
    Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
    N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup Analysis for Chinese Patients Included in the INPULSIS
    Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
    Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
    ; Zisman DA; Schwarz M; Anstrom KJ; Collard HR; Flaherty KR; Hunninghake GW
    N Engl J Med; 2010 Aug; 363(7):620-8. PubMed ID: 20484178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
    Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
    Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung function outcomes in the INPULSIS
    Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
    Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
    Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
    Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
    Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
    Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
    Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.